Ensartinib for certain advanced tumors other than lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests the drug ensartinib in people with advanced solid tumors (not lung cancer) that have an ALK or MET gene change. It may be an option if standard treatments are not working, not tolerated, or refused.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that is not lung cancer
- Your tumor has an ALK or MET gene change (tested by a standard method)
- You have no standard treatment options left, cannot tolerate them, or choose not to take them
- Your liver, kidneys, and bone marrow are working well enough
- You are able to take oral medications and follow the study schedule
- You are not pregnant or breastfeeding and do not have serious active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
This trial tests the targeted therapy drug ensartinib given after surgery to prevent lung cancer from coming back. It is only for people whose tumor has an ALK gene change and who are in early to moderately advanced stages after complete removal.
This trial tests a targeted therapy pill called ensartinib given before surgery for people with ALK-positive lung cancer. The goal is to see if it can shrink the tumor enough to make surgery more successful.
This trial tests an oral targeted therapy (Ensartinib) after surgery for patients with stage I ALK-positive lung cancer who have certain high-risk features. The goal is to see if it helps prevent cancer from returning.
This trial compares ensartinib with standard platinum-based chemotherapy as “adjuvant” treatment—medicine given after surgery to lower the chance the cancer comes back. It’s for people with stage IIA to IIIA ALK-positive non-small cell lung cancer who had their tumor surgically removed.
This trial tests whether taking ensartinib before surgery can help people with a specific type of lung cancer that has the ALK gene change. It is for those whose cancer is stage II or III and can be surgically removed.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.